5 stories mentioning HKG:2616Updated 4d ago
Every FINWIRES story that references HKG:2616, newest first.
CStone Pharmaceuticals (HKG:2616) received ethics approval to begin clinical trials of its core candidate CS5007 in Australia, according to a Friday filing with the Hong Kong bourse.The firm plans to enroll 310 patients in China and Australia to study the cancer treatment's effects.
CStone Pharmaceuticals (HKG:2616) intends to buy back up to nearly 136.5 million shares from the open market from time to time under a mandate approved June 25, 2025, according to a Wednesday Hong Kong bourse filing.The repurchase plan is expected to be implemented following the American Society of Clinical Oncology (ASCO) Annual Meeting.
CStone Pharmaceuticals (HKG:2616) began nationwide commercial supply of locally manufactured pralsetinib capsules in China, according to a Monday filing with the Hong Kong bourse.The oncology drugmaker said the first batch shipment marks the establishment of a localized supply chain for the therapy.CStone expects full-year 2026 sales revenue for pralsetinib capsules to exceed 300 million yuan, the filing said.
CStone Pharmaceuticals (HKG:2616) completed a share offering to raise about HK$1.05 billion in net proceeds, according to a Wednesday Hong Kong bourse filing.Shares of the company fell nearly 3% in late morning trade Thursday.The pharmaceutical firm placed 118 million new shares at HK$8.97 each to at least six independent investors.The placing shares represent about 7.40% of the company's enlarged issued share capital.Net proceeds will be used mainly for research and development of its oncology pipeline, with the remainder for general corporate purposes.
CStone Pharmaceuticals (HKG:2616) plans to raise about HK$1.05 billion in net proceeds through a share placement, according to a Wednesday Hong Kong bourse filing.The pharmaceutical firm agreed to place 118 million new shares at HK$8.97 each to at least six independent investors.The placing price represents a discount of about 7% to the last closing price and about 7.9% to the five-day average price, the filing said.The placing shares represent about 8% of the company's existing issued share capital.Net proceeds will be used mainly for research and development of its oncology pipeline, with the remainder for general corporate purposes.
